Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TPTX, SPY, FMTX, RVMD, CCXI, and represent 28.05% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: IMVT (+$58M), Alx Oncology Hldgs (+$36M), TRIL (+$36M), OMER (+$33M), ZYME (+$28M), ALBO (+$23M), OTIC (+$13M), TCRR (+$12M), BNTX (+$10M), Health Sciences Acq Corp 2 (+$8.8M).
- Started 16 new stock positions in TRIL, IMVT, Therapeutics Acquisition Cor, Fs Dev Corp, TCRR, Iteos Therapeutics, Vesper Healthcare Acq Unt, Panacea Acquisition Corp, Bctg Acquisition Corp, TARA. ALBO, CRDF, Health Sciences Acq Corp 2, MORF, OTIC, Alx Oncology Hldgs.
- Reduced shares in these 10 stocks: Principia Biopharma (-$95M), CCXI (-$58M), MRTX (-$37M), TPTX (-$26M), STSA (-$23M), MYOK (-$20M), NXTC (-$15M), BBIO (-$12M), XLRN (-$11M), AGEN (-$10M).
- Sold out of its positions in BNR, NXTC, Principia Biopharma, STSA, XFOR, ARYBU.
- Cormorant Asset Management was a net seller of stock by $-147M.
- Cormorant Asset Management has $2.6B in assets under management (AUM), dropping by -0.77%.
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Companies in the Cormorant Asset Management portfolio as of the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Turning Point Therapeutics I (TPTX) | 8.2 | $213M | -10% | 2.4M | 87.36 | |
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 6.4 | $167M | 500k | 334.89 | ||
| Forma Therapeutics Hldgs SHS (FMTX) | 6.4 | $167M | 3.4M | 49.26 | ||
| Revolution Medicines (RVMD) | 3.5 | $92M | 2.6M | 34.80 | ||
| Chemocentryx (CCXI) | 3.5 | $90M | -38% | 1.7M | 54.80 | |
| Bridgebio Pharma (BBIO) | 3.3 | $85M | -12% | 2.3M | 37.52 | |
| Ishares Tr Russell 2000 Etf Put Option (IWM) | 2.9 | $75M | 500k | 149.79 | ||
| Sorrento Therapeutics Com New (SRNE) | 2.8 | $73M | 6.5M | 11.15 | ||
| Avidity Biosciences Ord (RNA) | 2.7 | $70M | 2.5M | 27.65 | ||
| Myokardia (MYOK) | 2.4 | $61M | -25% | 450k | 136.33 | |
| Omeros Corporation (OMER) | 2.3 | $61M | +116% | 6.0M | 10.11 | |
| Immunovant (IMVT) | 2.2 | $58M | NEW | 1.6M | 35.19 | |
| Apellis Pharmaceuticals (APLS) | 2.2 | $56M | -9% | 1.9M | 30.17 | |
| Acceleron Pharma (XLRN) | 2.2 | $56M | -16% | 500k | 112.53 | |
Setup an alertCormorant Asset Management will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 2.1 | $56M | 500k | 111.43 | ||
| Y Mabs Therapeutics (YMAB) | 2.1 | $54M | -11% | 1.4M | 38.39 | |
| Zymeworks (ZYME) | 2.1 | $54M | +109% | 1.2M | 46.58 | |
| Stoke Therapeutics (STOK) | 2.0 | $52M | -9% | 1.5M | 33.49 | |
| Eidos Therapeutics (EIDX) | 1.9 | $50M | -5% | 993k | 50.53 | |
| Mirati Therapeutics (MRTX) | 1.8 | $46M | -45% | 275k | 166.05 | |
| Viela Bio (VIE) | 1.7 | $45M | +4% | 1.6M | 28.08 | |
| Reata Pharmaceuticals Cl A (RETA) | 1.7 | $44M | +12% | 450k | 97.42 | |
| Twist Bioscience Corp (TWST) | 1.5 | $38M | -9% | 500k | 75.97 | |
| Alx Oncology Hldgs | 1.4 | $36M | NEW | 972k | 37.00 | |
| Trillium Therapeutics Com New (TRIL) | 1.4 | $36M | NEW | 2.5M | 14.21 | |
| Axonics Modulation Technolog (AXNX) | 1.4 | $35M | -3% | 693k | 51.04 | |
| Agenus Com New (AGEN) | 1.3 | $34M | -22% | 8.5M | 4.00 | |
| Biohaven Pharmaceutical Holding (BHVN) | 1.2 | $33M | -16% | 500k | 65.01 | |
| Rocket Pharmaceuticals (RCKT) | 1.2 | $31M | -6% | 1.4M | 22.86 | |
| Arcturus Therapeutics Hldg I (ARCT) | 1.2 | $30M | -12% | 700k | 42.90 | |
| Myovant Sciences (MYOV) | 1.2 | $30M | -14% | 2.1M | 14.05 | |
| Akero Therapeutics (AKRO) | 1.0 | $27M | +45% | 860k | 30.79 | |
| Blueprint Medicines (BPMC) | 1.0 | $26M | -21% | 275k | 92.70 | |
| Crispr Therapeutics Namen Akt (CRSP) | 1.0 | $25M | -25% | 300k | 83.64 | |
| Albireo Pharma (ALBO) | 0.9 | $23M | NEW | 700k | 33.37 | |
| Biontech Se Sponsored Ads (BNTX) | 0.9 | $22M | +85% | 325k | 68.95 | |
| Cabaletta Bio (CABA) | 0.9 | $22M | 2.1M | 10.84 | ||
| Beam Therapeutics (BEAM) | 0.8 | $20M | 796k | 24.62 | ||
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.7 | $19M | -28% | 125k | 154.32 | |
| Galapagos Nv Spon Adr (GLPG) | 0.7 | $19M | +31% | 130k | 142.08 | |
| Axsome Therapeutics (AXSM) | 0.7 | $18M | -28% | 250k | 71.25 | |
| Igm Biosciences (IGMS) | 0.6 | $17M | -33% | 225k | 73.81 | |
| Zai Lab Adr (ZLAB) | 0.6 | $16M | -24% | 189k | 83.17 | |
| Inspire Med Sys (INSP) | 0.6 | $16M | -18% | 120k | 129.05 | |
| Kura Oncology (KURA) | 0.6 | $15M | -28% | 500k | 30.64 | |
| Pliant Therapeutics (PLRX) | 0.5 | $14M | 611k | 22.20 | ||
| Otonomy (OTIC) | 0.5 | $13M | NEW | 3.2M | 4.05 | |
| Deciphera Pharmaceuticals (DCPH) | 0.5 | $13M | -21% | 250k | 51.30 | |
| Tcr2 Therapeutics Inc cs (TCRR) | 0.5 | $12M | NEW | 600k | 20.32 | |
| Uniqure Nv SHS (QURE) | 0.5 | $12M | -26% | 325k | 36.83 | |
| Sarepta Therapeutics (SRPT) | 0.5 | $12M | -22% | 85k | 140.44 | |
| Insmed Com Par $.01 (INSM) | 0.4 | $11M | -22% | 350k | 32.14 | |
| Akouos (AKUS) | 0.4 | $11M | 500k | 22.41 | ||
| Repare Therapeutics Ord (RPTX) | 0.4 | $11M | 349k | 30.77 | ||
| Argenx Se Sponsored Adr (ARGX) | 0.4 | $11M | -42% | 40k | 262.52 | |
| Quotient SHS (QTNT) | 0.4 | $10M | -31% | 2.0M | 5.14 | |
| Harpoon Therapeutics (HARP) | 0.4 | $9.7M | -11% | 571k | 16.99 | |
| Theravance Biopharma (TBPH) | 0.4 | $9.6M | +550% | 650k | 14.78 | |
| Anaptysbio Inc Common (ANAB) | 0.4 | $9.6M | -26% | 650k | 14.75 | |
| Health Sciences Acq Corp 2 Ord Shs | 0.3 | $8.8M | NEW | 800k | 11.00 | |
| Iteos Therapeutics | 0.3 | $8.6M | NEW | 350k | 24.67 | |
| Bctg Acquisition Corp | 0.3 | $8.4M | NEW | 800k | 10.46 | |
| Protara Therapeutic Com Stk (TARA) | 0.3 | $7.6M | NEW | 450k | 16.83 | |
| Therapeutics Acquisition Cor Com Cl A | 0.3 | $7.2M | NEW | 500k | 14.38 | |
| Morphic Hldg (MORF) | 0.3 | $6.8M | NEW | 250k | 27.34 | |
| Tricida (TCDA) | 0.3 | $6.6M | -16% | 728k | 9.06 | |
| Allakos (ALLK) | 0.2 | $6.1M | -62% | 75k | 81.45 | |
| Genetron Hldgs Ads (GTH) | 0.2 | $6.0M | 500k | 11.94 | ||
| Aveo Pharmaceuticals Com New (AVEO) | 0.2 | $5.9M | -25% | 1.0M | 5.94 | |
| Fs Dev Corp Com Cl A | 0.2 | $5.6M | NEW | 500k | 11.20 | |
| Merus N V (MRUS) | 0.2 | $5.2M | -28% | 429k | 12.00 | |
| Homology Medicines (FIXX) | 0.2 | $5.0M | -14% | 471k | 10.70 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $4.9M | -12% | 422k | 11.64 | |
| Kezar Life Sciences (KZR) | 0.2 | $4.5M | -28% | 932k | 4.84 | |
| Vesper Healthcare Acqstn Cor Unit 99/99/9999 | 0.2 | $4.1M | NEW | 400k | 10.26 | |
| Atreca Cl A Com (BCEL) | 0.2 | $4.1M | -8% | 294k | 13.97 | |
| Kadmon Hldgs (KDMN) | 0.2 | $3.9M | -44% | 1.0M | 3.92 | |
| Eiger Biopharmaceuticals (EIGR) | 0.1 | $3.7M | -35% | 450k | 8.14 | |
| Avrobio Ord (AVRO) | 0.1 | $3.2M | -23% | 244k | 13.02 | |
| Gossamer Bio (GOSS) | 0.1 | $3.1M | -28% | 248k | 12.41 | |
| Panacea Acquisition Corp Unit 99/99/9999 | 0.1 | $3.0M | NEW | 250k | 12.00 | |
| Cardiff Oncology (CRDF) | 0.1 | $2.5M | NEW | 175k | 14.19 | |
| Arena Pharmaceuticals Com New (ARNA) | 0.1 | $2.2M | -60% | 30k | 74.80 | |
| Precision Biosciences Ord (DTIL) | 0.1 | $2.1M | 347k | 6.16 | ||
| Amarin Corp Spons Adr New (AMRN) | 0.0 | $1.3M | -50% | 300k | 4.21 | |
| Orchard Therapeutics Ads (ORTX) | 0.0 | $1.1M | 257k | 4.11 | ||
| Nektar Therapeutics (NKTR) | 0.0 | $830k | -60% | 50k | 16.60 | |
| Minerva Neurosciences (NERV) | 0.0 | $759k | -53% | 239k | 3.18 | |
| Fate Therapeutics (FATE) | 0.0 | $600k | -70% | 15k | 40.00 | |
| Outlook Therapeutics *w Exp 02/18/202 (OTLKW) | 0.0 | $54k | 417k | 0.13 | ||
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2020 Q3 filed Nov. 16, 2020
- Cormorant Asset Management 2020 Q2 filed Aug. 14, 2020
- Cormorant Asset Management 2020 Q1 filed May 15, 2020
- Cormorant Asset Management 2019 Q4 filed Feb. 14, 2020
- Cormorant Asset Management 2019 Q3 filed Nov. 14, 2019
- Cormorant Asset Management 2019 Q2 filed Aug. 14, 2019
- Cormorant Asset Management 2019 Q1 filed May 15, 2019
- Cormorant Asset Management 2018 Q4 filed Feb. 14, 2019
- Cormorant Asset Management 2018 Q3 filed Nov. 14, 2018
- Cormorant Asset Management 2018 Q2 filed Aug. 14, 2018
- Cormorant Asset Management 2018 Q1 filed May 15, 2018
- Cormorant Asset Management 2017 Q4 filed Feb. 14, 2018
- Cormorant Asset Management 2017 Q3 filed Nov. 14, 2017
- Cormorant Asset Management 2017 Q2 filed Aug. 14, 2017
- Cormorant Asset Management 2017 Q1 filed May 15, 2017
- Cormorant Asset Management 2016 Q4 filed Feb. 14, 2017